

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-10 canceled.

11. (currently amended) ~~A~~ An isolated peptide selected from

~~(a) a peptide comprising the amino acid sequence represented by SEQ ID NO:1;~~

~~(b)(a) a peptide comprising of the amino acid sequence represented by SEQ ID NO:2;~~

~~(e)(b) a peptide comprising of the amino acid sequence represented by SEQ ID NO:3; and~~

~~(d)(c) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:1, and of the amino acid sequence: X_n -Met-Ala-Pro- Y_m in which n is 0 or 1; m is 0 or 1; X is an amino acid residue; and Y is an amino acid residue, wherein said amino acid sequence having has activity of inhibiting angiotensin-converting enzyme and when n is 0, m is not 0;~~

~~(e) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:2, and having activity of inhibiting angiotensin-converting enzyme; and~~

~~(f) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:3, and having activity of inhibiting angiotensin-converting enzyme.~~

12. (previously presented) An inhibitor for an angiotensin-converting enzyme, which comprises the peptide according to claim 11 as an active ingredient.

13. (previously presented) A food or drink comprising the peptide according to claim 11.

14. (previously presented) A pharmaceutical composition comprising the peptide according to claim 11 as an active ingredient.

15. (currently amended) The food or drink according to claim 13, which is an agent for ~~preventing and/or~~ treating diseases caused by abnormality of an angiotensin-converting enzyme.

16. (currently amended) The pharmaceutical composition according to claim 14, which is an agent for ~~preventing and/or~~ treating diseases caused by abnormality of an angiotensin-converting enzyme.

17. (previously presented) A method of inhibiting an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.

18. (currently amended) A method of ~~preventing and/or~~ treating diseases caused by abnormality of an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.

19. (new): The isolated peptide of claim 11, wherein n is 1 and m is 0.

20. (new): The isolated peptide of claim 11, wherein n is 0 and m is 1.

21. (new): The isolated peptide of claim 19, wherein X is Leu or Arg.

22. (new): The isolated peptide of claim 20, wherein Y is Pro.

23. (new): The isolated peptide of claim 21, wherein n is 1, m is 1, X is Leu or Arg, and Y is Pro.

24. (new): A method of inhibiting an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide of SEQ ID NO:1.

25. (new): A method of treating diseases caused by abnormality of an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide of SEQ ID NO: 1.